Clinical Use of Cannabinoids for Symptom Control in Multiple Sclerosis

Neurotherapeutics

Volumn 12, Issue 4, 2015, Pages 769-777

  Notcutt, William G ^a  

^a JAMES PAGET UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Cannabinoids; multiple sclerosis; nabiximols; pain

Indexed keywords

CANNABINOID; DRONABINOL; NABILONE; NABIXIMOLS; RECREATIONAL DRUG; ENDOCANNABINOID;

BREAKTHROUGH PAIN; CANNABIS USE; CAR DRIVING; CLINICAL PRACTICE; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG OVERDOSE; DRUG WITHDRAWAL; HUMAN; MULTIPLE SCLEROSIS; MUSCLE SPASM; NEUROLOGIC DISEASE; NEUROPATHIC PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SPASTICITY; TREATMENT DURATION; TREATMENT OUTCOME; METABOLISM; PATHOPHYSIOLOGY;

CANNABINOIDS; ENDOCANNABINOIDS; HUMANS; MULTIPLE SCLEROSIS;

EID: 84958151062     PISSN: 19337213     EISSN: 18787479     Source Type: Journal    
DOI: 10.1007/s13311-015-0383-5     Document Type: Review

References (52)

1. Scotter EL, Abood ME, Glass M. The endocannabinoid system as a target for the treatment of neurodegenerative disease. Br J Pharmacol 2010;160:480-498.
2. National Institute for Health and Care Excellence. Multiple sclerosis. Management of multiple sclerosis in primary and secondary care. NICE clinical guideline 186. Available at: http://guidance.nice.org.uk/cg186. Accessed 17 Aug 2015.
3. Pertwee RG. Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities. Philos Trans R Soc Lond B Biol Sci 2012;367:3353-3363
4. Skaper RD, Di Marzo V. Why do cannabinoid receptors have more than one endogenous ligand? Philos Trans R Soc Lond B Biol Sci 2012;367:3216-3228.
5. Notcutt W, Clarke E. Cannabinoids in clinical practice: A UK perspective. In: Pertwee R (ed.) Handbook of cannabis, Oxford University Press, Oxford, 2014; p. 415-432
6. Wade DT, Collin C, Stott C, Duncombe P. Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis. Mult Scler 2010;16, 707-714.
7. Novotna, A., Mares, J., Ratcliffe, S. et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol 2011;18:1122-1131.
8. Vermersch P. Sativex® (Tetrahydrocannabinol + Cannabidiol), an endocannabinoid system modulator: basic features and main clinical data. Exp Rev Neurother 2011;11:15-19.
9. Collin C, Ehler E, Waberzinek G, et al. A double-blind, randomized, placebo controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol Res 2010;32:451-459.
10. Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis based medicine in central pain in multiple sclerosis. Neurology 2005;65:812-819.
11. Brady CM, DasGupta R, Dalton C, et alAn open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis. Mult Scler 2004;10:425-433.
12. Zajicek J, Fox P, Sanders H, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 2003;362:1517-1526.
13. Zajicek JP, Hobart JC, Slade A, Barnes D, Mattison PG. Multiple sclerosis and extract of cannabis: results of the MUSEC trial. J Neurol Neurosurg Psychiatry 2012;83:1125-1132.
14. Serpell M, Notcutt W, Collin C. Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis. J Neurol 2013;260:285-295.
15. Notcutt W, Langford R, Davies P, Ratcliffe S, Potts R. A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex® (nabiximols). Mult Scler 2012;18:219-228.
16. Notcutt WG. A questionnaire survey of patients and carers of patients prescribed Sativex as an unlicensed medicine. Prim Health Care Res Dev 2012;12:1-8.
17. Nurmikko TJ, Serpell MG, Hoggart B, et al. Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain 2007;133:210-220.
18. Abrams DI, Jay CA, Shade SB, et al. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology 2007;68:515-21.
19. Ellis RJ, Toperoff W, Vaida F, et al. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology 2009;34:672-680.
20. Lynch ME, Campbell F. Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. Br J Clin Pharmacol 2011;72:735-744.
21. Cichewicz DL, Martin ZL, Smith FL, Welch SP. Enhancement mu opioid antinociception by oral delta9-tetrahydrocannabinol: dose-response analysis and receptor identification. J Pharmacol Exp Ther 1999;289:859-67.
22. Karst M, Wippermann S, Ahrens J. Role of cannabinoids in the treatment of pain and (painful) spasticity. Drugs 2010;70:2409-2438.
23. Russo E. Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuroendocrinol Lett 2004;25:31-39.
24. Devinsky O, Cilio M, Cross H, et al. Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia 2014;55:791-802.
25. Ware MA, Fitzcharles MA, Joseph L, Shir Y. The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesth Analg 2010;110(2):604-10.
26. Hall W. The respiratory risks of cannabis smoking. Addiction 1998;93:1461-1463.
27. Henry JA, Oldfield WLG, Kon OM. Comparing cannabis with tobacco. BMJ 2003;326:942-943.
28. Johnson C. Shared care guideline: Nabilone in the management of chronic neuropathic pain that has failed to respond to other first and second line treatments. NHS Lincolnshire in Association with United Lincolnshire Hospitals Trust, 2013. https://www.google.co.uk/?gws_rd=ssl#q=nabilone+licensed+indications.
29. Flynn J, Hanif N. Nabilone for the management of intractable nausea and vomiting in terminally staged AIDS. J Palliat Care 1992;8:46-47.
30. Notcutt W, Phillip C, Hughe J, LacouX P, Vijayakulasingam V, Baldock L. A retrospective description of the use of nabilone in uk clinical practice – extension study. British Pain Society Annual Scientific Meeting 2015, Glasgow: Poster Presentation; 2015.
31. Russo E, Guy GW. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and Cannaidiol. Med Hypotheses 2006;66:234-246.
32. Notcutt W, Price M, Chapman G. Clinical experience with nabilone for chronic pain. Pharm Sci 1997;3:551-555.
33. GW Pharmaceuticals. Sativex—summary of product characteristics. Available at: http://www.gwpharm.com/. Accessed 17 Aug 2015.
34. Johnson JR, Burnell-Nugent M, Lossignol D, et al. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC: CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manag 2010;39:167-179.
35. Strasser F, Luftner D, Possinger K, et al. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. J Clin Oncol 2006;24:3394-3400
36. Nutt DJ, King LA, Phillips LD. Independent Scientific Committee on Drugs. Drug harms in the UK: a multicriteria decision analysis. Lancet 2010;376:1558-1565.
37. Schoedel KA, Chen N, Hilliard A, et al. A randomized, double blind, placebo controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use. Hum Psychopharmacol 2011;26:224-236.
38. Calhoun SR, Galloway GP, Smith DE. Abuse potential of dronabinol (Marinol). J Psychoactive Drugs 1998;30:187-196.
39. Ware MA, St Arnaud-Trempe E. The abuse potential of the synthetic cannabinoid nabilone. Addiction 2010;105:494-503.
40. Wade D. Evaluation of the safety and tolerability profile of Sativex: is it reassuring enough? Exp Rev Neurother 2012;12:9-14.
41. Robson P. Abuse potential and psychoactive effects of d-9-tetrahydrocannabinol and Cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine. Exp Opin Drug Saf 2011;10:675-685.
42. Henquet C, Krabbendam L, Spauwen J, et al. Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ 2005;330:11.
43. Degenhardt L, Hall W. Cannabis and psychosis. Curr Psychiatry Rep 2002;4:191-196.
44. Aragona M, Onesti E, Tomassini V, et al. Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study. Clin Neuropharmacol 2009;32:41-47.
45. Johns A. Pyschiatric effects of cannabis. Br J Psychiatry 2001;178:116-122.
46. Sexton BF, Tunbridge RJ, Brook-Carter N, et al. The influence of cannbis on driving. UK Transport Research Laboratory, Report 477, 2000. Available at: http://www.erowid.org/plants/cannabis/cannabis_driving6.pdf. Accessed 17 Aug 2015.
47. Asbridge M, Hayden JA, Cartwright JL. Acute cannabis consumption and motor vehicle collision risk: systematic review of observational studies and meta-analysis. BMJ 2012;344:e536.
48. Englehart K, Sexton BF, Tunbridge RJ, et al. The influence of cannabis on driving. Available at: http://www.erowid.org/plants/cannabis/cannabis_driving6.pdf. Accessed 17 Aug 2015.
49. Slof J, Gras A. Sativex® in multiple sclerosis spasticity: a cost-effectiveness model. Expert Rev Pharmacoecon Outcomes Res 2012;12:525-538.
50. Flachenecker P. A new multiple sclerosis spasticity treatment option: effect in everyday clinical practice and cost-effectiveness in Germany. Exp Rev Neurother 2013;13(3 Suppl. 1):15-19.
51. AWMSG Secretariat Assessment Report. Delta-9-tetrahydrocannabinol/ Cannabidiol (Sativex®). All Wales Therapeutics and Toxicology Centre. Reference number: 644. July 2014.
52. Shakespeare DT, Boggild M, Young C. Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst Rev 2003;(4):CD001332.